Latest research shows benefit of non-invasive, high-plex protein profiling for liver disease

Pharma researchers use non-invasive SomaSignal® tests to advance understanding and treatment strategies for liver disease and NASH

Exciting new discoveries have been made recently by researchers using the NASH bundle of SomaSignal® tests as a non-invasive, liquid biopsy approach to identify novel protein biomarkers related to liver disease and non-alcoholic steatohepatitis (NASH). See below for recent research from our pharma partners. Want to discuss these results or learn how high-plex protein profiling could accelerate your research? Contact us today.

Preview of Anne Minnich, PhD Webinar

Correlation of a nonalcoholic steatohepatitis proteomic test with clinical outcomes

Anne Minnich, PhD, biomarker consultant at Bristol Myers Squibb, presented published research on the use of the SomaSignal NASH bundle in the recently completed FALCON 1 Phase IIb multicenter trial investigating the use of three pegbelfermin doses in patients with NASH.

Watch webinar

Preview image of EASL poster - Utility Of

Utility of SomaSignal panels for drug response and monitoring disease progression in patients with advanced fibrosis due to nonalcoholic steatohepatitis

Researchers from Liver Institute Northwest, Washington State University, Gilead Sciences, Houston Research Institute, and NAFLD Research Center – University of California San Diego presented results from the Phase IIb ATLAS trial that showed SomaSignal test scores for NASH are significantly associated with histologically assessed NASH Clinical Research Network (CRN) scores and may thus be useful for noninvasive assessment of treatment responses in NASH clinical trials.

Download poster

EASL poster - Semaglutide

Semaglutide reduced the odds of having NASH components in populations with overweight/obesity, as measured by SomaSignal models

Researchers from University Medical Center Mainz, Aarhus University Hospital, Novo Nordisk, Virginia Commonwealth University, Diabetes Research Centre – University of Leicester, and NIHR Leicester Biomedical Research Centre applied data from two Phase IIIa weight loss trials and one Phase IIb trial and found semaglutide had a favorable effect on NASH components in patients with overweight/obesity, with and without Type 2 diabetes.

Download poster

Want to learn more about SomaSignal tests for pharma research?

Our SomaSignal tests are based on a dataset of ~3 million protein measurements that we developed by analyzing thousands of patients using our high-plex, high-throughput SomaScan Assay. Learn more about the NASH bundle and all our SomaSignal tests here.

Want to know more about using high-plex, aptamer-based protein profiling for NASH research?

See more research, webinars, and our full SomaSignal test portfolio here. And click below to see how our proprietary SOMAmer®
(Slow Off-rate Modified Aptamer) protein affinity reagents work.

Have questions
or a unique challenge?

Our scientific team will help you find a solution.

Contact us

Want a quick update
when we publish new
NASH-related research?

Keep me updated

Share with colleagues

More posters

PosterProteomic Indicators of Metabolic Health in Diabetes and Social Deprivation

Understanding the health impacts of socioeconomic deprivation (SED) and its interaction with type 2 diabetes is important for patient care and effective public health initiatives. Large-scale proteomic profiling using aptamer-based technology to measure 7,000 proteins has facilitated the development of blood-based proteomic signatures for 11 cardiometabolic SomaSignalTM Tests (SST)

Learn more

PosterHeritability, pQTLs, and environmental influence on proteins involved in age, cardiovascular risk, and glucose tolerance using the SomaScan® Assay

Protein quantitative trait locus (“pQTL”) studies identify genetic variants that are statistically associated with protein levels. Results from the growing number of pQTL studies can be combined with genome-wide association studies to identify proteins that underlie the genetic risk of disease, thus revealing the mechanisms of disease and potential drug targets.

Learn more

PosterThe Plasma Proteome as a Cardiovascular Disease Risk Assessment Tool in Cancer Survivors

Cardiovascular disease (CVD) is the most common non-cancer cause of death in cancer survivors and there is an unmet clinical need for easy, accurate, and safe CVD prognostic risk-stratification in adult cancer survivors. This study investigated whether a previously validated 27-plasma protein prognostic model for four-year cardiovascular (CV) events could have such a utility.

Learn more

Explore posters in our interactive viewer